Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.

Craig L. Slingluff,Steven P. Fling,Ileana S. Mauldin,Marc S. Ernstoff,Brent A. Hanks,Keith A. Delman,David H. Lawson,Brian R. Gastman,Judith C. Kaiser,Martin A. Cheever

Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.

2018

Craig L. Slingluff
Steven P. Fling
Ileana S. Mauldin
Marc S. Ernstoff
Brent A. Hanks
Keith A. Delman
David H. Lawson
Brian R. Gastman
Judith C. Kaiser
Martin A. Cheever

3033Background: Melanoma metastases limit infiltration and function of antitumor T cells in part by immunosuppression with IDO1. INCB024360 (epacadostat) is an IDO1 inhibitor that normalizes serum ...

Keywords:

Melanoma
Melanoma Vaccine
Pathology
Cancer research
Medicine
Indoleamine 2,3-dioxygenase
Epacadostat
Immunosuppression
advanced melanoma
in patient
Oncology
pilot trial
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations